SGLT2 inhibitors can be used for the secondary prevention of cardiovascular outcomes in patients with T2DM and a history of cardiovascular disease in consideration of their beneficial cardiovascular and metabolic effects. Here, SLC5A2 is linked to type 2 diabetes mellitus.